Contributions from the systematic review of economic evaluations: The case of childhood hepatitis A vaccination in Brazil;Contribuições da revisão sistemática de avaliações econômicas: O exemplo da vacinação infantil contra hepatite A no Brasil

Cadernos de Saude Publica

Volumn 28, Issue 2, 2012, Pages 211-228

  De Soárez, Patrícia Coelho ^a   Sartori, Ana Marli Christovam ^a   Santos, Andreia ^b   Itria, Alexander ^a   Novaes, Hillegonda Maria Dutilh ^a   Martelli, Celina Maria Turchi ^c,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cost Benefit Analysis; Cost Effectiveness Evaluation; Hepatitis A; Immunization Programs

Indexed keywords

HEPATITIS A VACCINE;

BRAZIL; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE POLICY; HUMAN; INFANT; NEWBORN; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; REVIEW; STANDARD;

BRAZIL; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH POLICY; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN;

EID: 84857286610     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/S0102-311X2012000200002     Document Type: Review

References (44)

1. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ 2010; 19:350-64.
2. Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ 2001; 322:1596-8.
3. Centre for Reviews and Disseminations, University of York. Systematic reviews. CRD's guidance for undertaking reviews in health care. York: Centre for Reviews and Disseminations, University of York; 2008.
4. Shemilt I, Mugford M, Byford S, Drummond M, Eisenstein E, Knapp M, et al. Chapter 15: incorporating economic evidence. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 5.0.0. The Cochrane Collaboration, 2008. http://www.cochrane-hand book.org.
5. Nothdurft HD. Hepatitis A vaccines. Expert Rev Vaccines 2008; 7:535-45.
6. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294:202-10.
7. Chodick G, Heymann AD, Ashkenazi S, Kokia E, Shalev V. Long-term trends in hepatitis A incidence following the inclusion of hepatitis A vaccine in the routine nationwide immunization program. J Viral Hepat 2008; 15 Suppl 2:62-5.
8. Vacchino MN. Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat 2008; 15 Suppl 2:47-50.
9. Zhou F, Shefer A, Weinbaum C, McCauley M, Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996-2004. Vaccine 2007; 25:3581-7.
10. Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepat 2008; 15 Suppl 2:1-15.
11. Bos JM, Alphen L, Postma MJ. The use of modeling in the economic evaluation of vaccines. Expert Rev Pharmacoecon Outcomes Res 2002; 2:443-55.
12. Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, et al. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 2008; 26:17-32.
13. de Alencar Ximenes RA, Martelli CM, Merchán-Hamann E, Montarroyos UR, Braga MC, de Lima ML, et al. Multilevel analysis of hepatitis A infection in children and adolescents: a household survey in the Northeast and Central-west regions of Brazil. Int J Epidemiol 2008; 37:852-61.
14. Jacobsen K. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Geneva: World Health Organization; 2009.
15. Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt J. Challenges in systematic reviews of economic analyses. Ann Intern Med 2005; 142(12 Pt 2):1073-9.
16. Hepatitis B vaccines. Wkly Epidemiol Rec 2009; 84:405-19.
17. Organization for Economic Co-operation and Development. Purchasing power parities (PPP). http://www.oecd.org/std/ppp (accessed on 20/Sep/2011).
18. US Department of Labor. US labor statistics data. Consumer Price Index. http://www.bls.gov/cpi/.
19. Zahdi MR, Maluf I, Maluf EM. Hepatitis A: the costs and benefits of the disease prevention by vaccine, Paraná, Brazil. Braz J Infect Dis 2009; 13:257-61.
20. Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology 1999; 29:548-52.
21. Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 2007; 119:e22-9.
22. Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 2003; 22:904-14.
23. Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007; 119:e12-21.
24. Ginsber GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 2001; 34:92-9.
25. Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005; 23:4110-9.
26. Quezada A, Baron-Papillon F, Coudeville L, Maggi L. Universal vaccination of children against hepatitis A in Chile: a cost-effectiveness study. Rev Panam Salud Pública 2008; 23:303-12.
27. Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 2007; 42:152-60.
28. Ellis A, Rüttimann RW, Jacobs RJ, Meyerhoff AS, Innis BL. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev Panam Salud Pública 2007; 21:345-56.
29. Zhuang GH, Pan XJ, Wang XL. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine 2008; 26:4608-16.
30. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002; 109:839-45.
31. Van Damme P, Banatvala J, Fay O, Iwarson S, Mc-Mahon B, Van Herck K, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362:1065-71.
32. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44:446-51.
33. Wiedermann G, Ambrosch F, André FE, D'Hondt E, Delem A, Safary A. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 1992; 10 Suppl 1:S129-31.
34. Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med 2000; 154:763-70.
35. Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000; 31:469-73.
36. Hauboldt R. Cost implications of human organ and tissue transplantation, an update. Seattle: Milliman & Robertson; 1999.
37. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-81.
38. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15:369-90.
39. Koslap-Petraco MB, Shub M, Judelsohn R. Hepatitis A: disease burden and current childhood vaccination strategies in the United States. J Pediatr Health Care 2008; 22:3-11.
40. Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, et al. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health 2010; 13:1028-37.
41. Drummond MF, Iglesias CP, Cooper NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves? Int J Technol Assess Health Care 2008; 24:146-50.
42. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8:iiiiv, 1-192.
43. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22:857-76.
44. Drummond M, Pang F. Transferability of economic evaluations results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001. p. 256-76.